强直性脊柱炎是一个以中轴骨炎症和骨质增生为特点的慢性免疫性疾病。目前的治疗策略主要包括非甾体抗炎药、基础量的糖皮质激素、肿瘤坏死因子抑制剂。然而，这些治疗的选择都不能满足耐药或不能耐受药物治疗的患者需求。促炎性细胞因子的白介素-17A（IL-17A）在AS的发病机制中起着至关重要的作用，它的出现有希望成为新的治疗方法。近年来，IL-17A抑制剂secukinumab已经证明可有效的降低AS的症状和体征。所覆盖的领域包括：IL-17A抑制剂secukinumab代表新的治疗方法对AS进行管理。Secukinumab有选择的抑制IL-17A与IL-17之间的相互作用，从而抑制促炎性细胞因子、趋化因子和组织损伤介质的释放。这里我们提供secukinumab治疗AS的药理学、临床疗效及其安全性综述。专家意见：Secukinumab在治疗免疫性疾病，如银屑病、银屑病性关节炎和AS均有很好的疗效及安全性。Secukinumab最近获得食品和药物管理局（FDA）和欧盟（EU）的批准用于治疗成年患者活动期AS，并且有可能在未来的5年发展成为确定的治疗方法。

附原文：AbstractINTRODUCTION:Ankylosing spondylitis (AS) is a chronic immune-mediated disease characterised by inflammation and new bone formation in the axial skeleton. Current therapeutic strategies include non-steroidal anti-inflammatory drugs, local glucocorticoids and tumour necrosis factor inhibitors. However, an unmet need exists for more treatment options particularly for patients who become unresponsive to and/or cannot tolerate these medications. Interleukin (IL)-17A, a proinflammatory cytokine that plays a crucial role in the pathogenesis of AS, has emerged as a promising target in the search for new therapies. Recently, the IL-17A inhibitor secukinumab has demonstrated significant efficacy in reducing the signs and symptoms of AS. Areas covered: Inhibition of IL-17A by secukinumab represents a novel therapeutic approach in the management of AS. Secukinumab selectively targets IL-17A and inhibits its interaction with the IL-17 receptor, thus inhibiting the release of proinflammatory cytokines, chemokines and mediators of tissue damage. Here we provide an overview of the pharmacology, clinical efficacy and safety of secukinumab in the treatment of AS. Expert opinion: Secukinumab has shown strong efficacy and a good safety profile in several immune-mediated diseases including psoriasis, psoriatic arthritis and AS. Secukinumab recently received Food and Drug Administration (FDA) and European Union (EU) approval for the treatment of adult patients with active AS and can be expected to become an established therapy for AS over the next 5 years.

引自：Braun J¹, Baraliakos X¹, Kiltz U¹. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016 Mar 16.